IL156578A0 - A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog - Google Patents
A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analogInfo
- Publication number
- IL156578A0 IL156578A0 IL15657802A IL15657802A IL156578A0 IL 156578 A0 IL156578 A0 IL 156578A0 IL 15657802 A IL15657802 A IL 15657802A IL 15657802 A IL15657802 A IL 15657802A IL 156578 A0 IL156578 A0 IL 156578A0
- Authority
- IL
- Israel
- Prior art keywords
- epothilone analog
- formulating
- pharmaceutical
- preparations including
- pharmaceutical preparations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26422801P | 2001-01-25 | 2001-01-25 | |
US29000601P | 2001-05-11 | 2001-05-11 | |
PCT/US2002/001813 WO2002058700A1 (en) | 2001-01-25 | 2002-01-22 | Methods of administering epothilone analogs for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
IL156578A0 true IL156578A0 (en) | 2004-01-04 |
Family
ID=26950348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15657802A IL156578A0 (en) | 2001-01-25 | 2002-01-22 | A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP4633331B2 (en) |
AU (1) | AU2002245296B2 (en) |
CA (1) | CA2434526C (en) |
HR (1) | HRP20030677B1 (en) |
IL (1) | IL156578A0 (en) |
MX (1) | MXPA03006412A (en) |
NO (1) | NO335119B1 (en) |
PL (1) | PL207720B1 (en) |
RU (1) | RU2292202C2 (en) |
WO (1) | WO2002058700A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AU2008200555C1 (en) * | 2003-03-14 | 2011-12-15 | Novartis Ag | Treatment of proliferative diseases with epothilone derivatives and radiation |
EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
ES2881391T3 (en) * | 2007-06-01 | 2021-11-29 | Wyeth Llc | Treatment of imatinib-resistant chronic myelogenous leukemia having the 1457T> C mutation in the BcrAbl gene using the compound bosutinib |
WO2009089138A1 (en) * | 2008-01-04 | 2009-07-16 | Bristol-Myers Squibb Company | Oral administration of ixabepilone |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
WO1999004330A1 (en) * | 1997-07-18 | 1999-01-28 | Hewlett-Packard Company | Format for passing information between devices |
US6365749B1 (en) * | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
AR017979A1 (en) * | 1998-02-05 | 2001-10-24 | Novartis Ag | PHARMACEUTICAL FORMULATIONS OF EPOTILONES, METHOD FOR THE PREPARATION AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
FR2775187B1 (en) * | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
EA009206B1 (en) * | 1999-02-18 | 2007-12-28 | Шеринг Акциенгезельшафт | 16-halogen-epothilone derivatives and their pharmaceutical use |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
-
2002
- 2002-01-22 RU RU2003126170/15A patent/RU2292202C2/en active
- 2002-01-22 PL PL373727A patent/PL207720B1/en unknown
- 2002-01-22 IL IL15657802A patent/IL156578A0/en not_active IP Right Cessation
- 2002-01-22 CA CA2434526A patent/CA2434526C/en not_active Expired - Lifetime
- 2002-01-22 JP JP2002559034A patent/JP4633331B2/en not_active Expired - Fee Related
- 2002-01-22 MX MXPA03006412A patent/MXPA03006412A/en active IP Right Grant
- 2002-01-22 WO PCT/US2002/001813 patent/WO2002058700A1/en active IP Right Grant
- 2002-01-22 AU AU2002245296A patent/AU2002245296B2/en not_active Ceased
-
2003
- 2003-07-24 NO NO20033341A patent/NO335119B1/en not_active IP Right Cessation
- 2003-08-25 HR HR20030677A patent/HRP20030677B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL373727A1 (en) | 2005-09-05 |
AU2002245296B2 (en) | 2006-12-21 |
NO20033341L (en) | 2003-09-04 |
WO2002058700A1 (en) | 2002-08-01 |
HRP20030677B1 (en) | 2011-10-31 |
RU2292202C2 (en) | 2007-01-27 |
RU2003126170A (en) | 2005-02-27 |
JP4633331B2 (en) | 2011-02-16 |
JP2005503323A (en) | 2005-02-03 |
HRP20030677A2 (en) | 2004-08-31 |
CA2434526A1 (en) | 2002-08-01 |
NO20033341D0 (en) | 2003-07-24 |
PL207720B1 (en) | 2011-01-31 |
CA2434526C (en) | 2011-11-01 |
NO335119B1 (en) | 2014-09-22 |
MXPA03006412A (en) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL156580A0 (en) | A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog | |
EP1391212A4 (en) | Oral preparations and supports for oral preparations | |
EP1367060A4 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | |
EP1364957A4 (en) | Glycopyranosyloxypyrazole derivatives and medicinal use thereof | |
EP1364958A4 (en) | Glycopyranosyloxypyrazole derivatives and medicinal use thereof | |
EP1248369A3 (en) | Proximity sensor and a method for operating same | |
AU2001280188A1 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
AU4694501A (en) | Protein capable of self-assembly at a hydrophobic-hydrophilic interface and usesthereof | |
AU2002362129A1 (en) | A universal electrocardiogram sensor positioning device and method for four sizes including extra large | |
AU2001262221A1 (en) | Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use | |
AU2002354476A1 (en) | Pyrazolopyridine derivatives and medicinal use thereof | |
AU2002339080A1 (en) | Apparatus and method for registering the position of a surgical robot | |
IL156578A0 (en) | A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog | |
PL360885A1 (en) | 10-aryl-11h-benzo [b]fluorene derivatives and analogs for medicinal use | |
PT1377578E (en) | Beta-carboline derivatives and its pharmaceutical use against depression and anxiety | |
AU2002360477A1 (en) | A dental impression method and device | |
HUP0401153A3 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
SI1581258T1 (en) | Pharmaceutical formulation and a method of making same | |
AU2001256953A1 (en) | Method and apparatus for biopotential sensing and stimulation | |
AU2002340328A1 (en) | Olanzapine dihydrate-ii a process for its preparation and use thereof | |
AU2992901A (en) | Method for preparing and administering medicinal plant material | |
AUPR916301A0 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
AUPR606401A0 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
AU2002211147A1 (en) | Apparatus for making dental inlays and the like | |
AUPR548601A0 (en) | Pyrazolopyrazinecompound and pharmaceutical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |